CONTEXT THERAPEUTICS INC (CNTX) Stock Fundamental Analysis

NASDAQ:CNTX • US21077P1084

2.25 USD
-0.03 (-1.32%)
At close: Feb 27, 2026
2.27 USD
+0.02 (+0.89%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall CNTX gets a fundamental rating of 3 out of 10. We evaluated CNTX against 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CNTX as it has an excellent financial health rating, but there are worries on the profitability. CNTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CNTX had negative earnings in the past year.
  • In the past year CNTX has reported a negative cash flow from operations.
  • CNTX had negative earnings in 4 of the past 5 years.
  • In the past 5 years CNTX always reported negative operating cash flow.
CNTX Yearly Net Income VS EBIT VS OCF VS FCFCNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of CNTX (-33.37%) is comparable to the rest of the industry.
  • CNTX has a Return On Equity of -36.13%. This is in the better half of the industry: CNTX outperforms 60.62% of its industry peers.
Industry RankSector Rank
ROA -33.37%
ROE -36.13%
ROIC N/A
ROA(3y)-71.84%
ROA(5y)235.37%
ROE(3y)-90.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTX Yearly ROA, ROE, ROICCNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

  • CNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTX Yearly Profit, Operating, Gross MarginsCNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CNTX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CNTX has more shares outstanding
  • There is no outstanding debt for CNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNTX Yearly Shares OutstandingCNTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CNTX Yearly Total Debt VS Total AssetsCNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • CNTX has an Altman-Z score of 18.24. This indicates that CNTX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 18.24, CNTX belongs to the top of the industry, outperforming 87.56% of the companies in the same industry.
  • CNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.24
ROIC/WACCN/A
WACCN/A
CNTX Yearly LT Debt VS Equity VS FCFCNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 13.10 indicates that CNTX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 13.10, CNTX belongs to the top of the industry, outperforming 82.38% of the companies in the same industry.
  • CNTX has a Quick Ratio of 13.10. This indicates that CNTX is financially healthy and has no problem in meeting its short term obligations.
  • CNTX's Quick ratio of 13.10 is amongst the best of the industry. CNTX outperforms 82.38% of its industry peers.
Industry RankSector Rank
Current Ratio 13.1
Quick Ratio 13.1
CNTX Yearly Current Assets VS Current LiabilitesCNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • CNTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.23%, which is quite impressive.
EPS 1Y (TTM)69.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CNTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.39% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y32.81%
EPS Next 2Y9.99%
EPS Next 3Y7.15%
EPS Next 5Y11.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTX Yearly Revenue VS EstimatesCNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M
CNTX Yearly EPS VS EstimatesCNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CNTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTX Price Earnings VS Forward Price EarningsCNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTX Per share dataCNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.99%
EPS Next 3Y7.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CNTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CONTEXT THERAPEUTICS INC

NASDAQ:CNTX (2/27/2026, 8:00:00 PM)

After market: 2.27 +0.02 (+0.89%)

2.25

-0.03 (-1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-25
Inst Owners75.25%
Inst Owner ChangeN/A
Ins Owners1.25%
Ins Owner Change0%
Market Cap206.73M
Revenue(TTM)N/A
Net Income(TTM)-26.44M
Analysts84
Price Target5.1 (126.67%)
Short Float %0.79%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.1%
Min EPS beat(2)-44.18%
Max EPS beat(2)-4.02%
EPS beat(4)2
Avg EPS beat(4)6.18%
Min EPS beat(4)-44.18%
Max EPS beat(4)57.74%
EPS beat(8)4
Avg EPS beat(8)-0.23%
EPS beat(12)5
Avg EPS beat(12)-12.53%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.83
P/tB 2.83
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.37%
ROE -36.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.84%
ROA(5y)235.37%
ROE(3y)-90.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 278.69%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.1
Quick Ratio 13.1
Altman-Z 18.24
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)155.66%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y32.81%
EPS Next 2Y9.99%
EPS Next 3Y7.15%
EPS Next 5Y11.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.41%
OCF growth 3YN/A
OCF growth 5YN/A

CONTEXT THERAPEUTICS INC / CNTX FAQ

Can you provide the ChartMill fundamental rating for CONTEXT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to CNTX.


What is the valuation status of CONTEXT THERAPEUTICS INC (CNTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to CONTEXT THERAPEUTICS INC (CNTX). This can be considered as Overvalued.


How profitable is CONTEXT THERAPEUTICS INC (CNTX) stock?

CONTEXT THERAPEUTICS INC (CNTX) has a profitability rating of 1 / 10.